Oppenheimer Reiterates Corvus Pharmaceuticals (CRVS) at Outperform, 'anticipate the stock will move higher on this news'
Tweet Send to a Friend
Oppenheimer analyst Jeff Jones reiterated an Outperform rating and $14.00 price target on Corvus Pharmaceuticals (NASDAQ: CRVS).The analyst commented: "This ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
